Phenotypic analysis of tumor-infiltrating lymphocytes in hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 54, Issue 77, 2007, Pages 1529-1533

  Chen, Chien Hung ^a   Lee, Hsuan Shu ^a   Huang, Guan Tarn ^a   Yang, Pei Ming ^a   Yu, Wei An ^a   Cheng, Kuang Chun ^a   Lee, Po Huang ^a   Jeng, Yung Ming ^a   Chen, Ding Shinn ^a   Sheu, Jin Chuan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hepatocellular carcinoma; Liver infiltrating lymphocytes; Regulatory T cells; Tumor infiltrating lymphocytes

Indexed keywords

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MALE; PHENOTYPE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PHENOTYPE;

EID: 34547640483     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Chen DS: Hepatitis B virus infection, its sequelae, and prevention in Taiwan. In: Okuda K, Ishak KG (Eds.). Neoplasms of the liver. Tokyo: Springer-Verlag, 1987; pp. 71-80.
2. Sheu JC, Sung JL, Chen DS, Lai MY, Wang TH, Yu JY, Yang PM, Chuang CN, Yang PC, Lee CS, Chen DS: Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 1985; 56:660-666.
3. Venook AP: Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994; 12:1323-1334.
4. Pardoll DM: Cancer vaccines. Nat Med 1998; 4:525-531.
5. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M: Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999; 48:353-362.
6. +) cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Clin Immunol 2001; 101:264-269.
7. Yuen MF, Hughes RD, Heneghan MA, Langley PG, Norris S: Expression of Fas antigen (CD95) in peripheral blood lymphocytes and in liver-infiltrating, cytotoxic lymphocytes in patients with hepatocellular carcinoma. Cancer 2001; 92:2136-2141.
8. Yoong KF, Afford SC, Jones R, Aujla P, Qin S, Price K, Hubscher SG, Adams DH: Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology 1999; 30:100-111.
9. Yoong KF, McNab G, Hubscher SG, Adams DH: Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 1998; 160:3978-3988.
10. Shimizu Y, Watanabe A, Whiteside TL: Memory T-lymphocytes are the main population of tumor-infiltrating lymphocytes obtained from human primary liver tumors. J Hepatol 1992; 16:197-202.
11. Doherty DG, O'Farrelly C: Innate and adaptive lymphoid cells in the human liver. Immunol Rev 2000; 174:5-20.
12. Kita H, Mackay IR, Van De Water J, Gershwin ME: The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 2001; 120:1485-1501.
13. Wood JCS: UNIT 1.8 Principles of Gating. In: Paul J, Robinson ZD, Dean PN, Hibbs AR, Orfao A, Rabinovitch PS, Wheeless LL (Eds.). Current Protocols in Cytometry: John Wiley & Sons, Inc, 2004.
14. Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M: Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998; 27:407-414.
15. + T-cell immunity against the parental tumor. Mol Ther 2001; 4:427-437.
16. Hardy CL, Bhathal PS, Snibson KJ, Adams TE: Comparison of intrahepatic lymphocytes from normal and growth hormone transgenic mice with chronic hepatitis and liver cancer. Immunology 1997; 90:412-420.
17. + NK cells in vitro. J Immunol 2000; 165:1659-1664.
18. +)T cells preferentially accumulate in human liver. Eur J Immunol 1999; 29:2406-2413.
19. Sheu BC, Lin RH, Ho HN, Huang SC: Down-regulation of CD25 expression on the surface of activated tumor-infiltrating lymphocytes in human cervical carcinoma. Hum Immunol 1997; 56:39-48.
20. Coventry BJ, Weeks SC, Heckford SE, Sykes PJ, Bradley J, Skinner JM: Lack of IL-2 cytokine expression despite Il-2 messenger RNA transcription in tumor-infiltrating lymphocytes in primary human breast carcinoma: selective expression of early activation markers. J Immunol 1996; 156:3486-3492.
21. Kolenko V, Wang Q, Riedy MC, O'Shea J, Ritz J, Cathcart MK, Rayman P, Tubbs R, Edinger M, Novick A, Bukowski R, Finite J: Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 1997; 159:3057-3067.
22. Lopez CB, Rao TD, Feiner H, Shapiro R, Marks JR, Frey AB: Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cell Immunol 1998; 190:141-155.
23. Yoong KF, Adams DH: Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases. Br J Cancer 1998; 77:1072-1081.
24. + T-cell subset among tumor-infiltrating lymphocytes in human renal cell carcinoma. Int J Cancer 1997; 71:178-182.
25. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, et al: T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 1993; 53:1380-1387.
26. Theze J, Alzari PM, Bertoglio J: Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol Today 1996; 17:481-486.
27. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH: A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001; 61:237-242.
28. Arthur MJ: Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000; 279:G245-249.
29. Lee HS, Huang GT, Chen CH, Chiou LL, Lee CC, Yang PM, Chen DS, Sheu JC: Less reversal of liver fibrosis after prolonged carbon tetrachloride injection. Hepatogastroenterology 2001; 48:1312-1315.
30. Lee HS, Huang GT, Miau LH, Chiou LL, Chen CH, Sheu JC: Expression of matrix metalloproteinases in spontaneous regression of liver fibrosis. Hepatogastroenterology 2001; 48:1114-1117.
31. Benyon RC, Arthur MJ: Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21:373-384.
32. Goetzl EJ, Banda MJ, Leppert D: Matrix metalloproteinases in immunity. J Immunol 1996; 156:1-4.
33. + T cells. Immunology 2002; 107:5-9.
34. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389-400.
35. Wood KJ, Sakaguchi S: Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3:199-210.
36. +) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61:4766-4772.
37. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-2761.
38. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH: Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168:4272-4276.
39. + regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 2002; 62:5267-5272.